The company’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over other ...

Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...

Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Mural Oncology in a research ...

Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis Continued demonstration of favorable tolerability ...

Mural Oncology (NASDAQ:MURA – Get Free Report) was downgraded by stock analysts at Raymond James from a “strong-buy” rating ...

H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Mural Oncology (MURA) to $6 from $18 and keeps a Buy rating on the ...

A Waltham company pulled the plug on a Phase 3 cancer trial, while a different Waltham company continued its leadership ...